Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder: (Trial 144: A Randomized Controlled Study)
Open accessThe DOI matches its Crossref record.
Abstract
Article Abstract Objective: Quetiapine, combined with lithium or divalproex, demonstrates efficacy in the maintenance treatment of bipolar I disorder. This study investigated the efficacy and safety of quetiapine monotherapy as maintenance treatment in bipolar I disorder compared with switching to placebo or lithium. Method: Patients aged ≥ 18 years with DSM-IV-diagnosed bipolar I disorder and a current or recent manic, depressive, or mixed episode received open-label quetiapine (300-800 mg/d) for 4-24 weeks. Patients achieving stabilization were randomized to continue quetiapine or to switch to placebo or lithium (0.6-1.2 mEq/L) for up to 104 weeks in a double-blind trial. Outcome measures included times to recurrence of any mood event (primary outcome measure), manic event, or depressive event. Safety assessments included adverse events and laboratory values. The study was terminated early after planned interim analysis provided positive results. The study was conducted between March 2005 and July 2007. Results: Of 2,438 patients starting open-label quetiapine, 1,226 (50.3%) were randomized to double-blind treatment, including 1,172 (95.6%) in the intent-to-treat population. Time to recurrence of any mood event was significantly longer for quetiapine versus placebo (hazard ratio = 0.29; 95% CI, 0.23-0.38; P < .0001) and for lithium versus placebo (HR = 0.46; 95% CI, 0.36-0.59; P < .0001). Quetiapine and lithium significantly increased time to recurrence of both manic events (quetiapine: HR = 0.29; 95% CI, 0.21-0.40; P < .0001; lithium: HR = 0.37; 95% CI, 0.27-0.53; P < .0001) and depressive events (quetiapine: HR = 0.30; 95% CI, 0.20-0.44; P < .0001; lithium: HR = 0.59; 95% CI, 0.42-0.84; P < .004) compared with placebo. Overall rates of adverse events were generally similar between treatment groups, and safety findings for quetiapine were consistent with its known profile. Conclusions: In patients stabilized during acute quetiapine treatment, continuation of quetiapine significantly increased time to recurrence of any mood, manic, or depressive event compared with switching to placebo. Switching to lithium was also more effective than placebo for the prevention of manic and depressive events. Trial Registration: clinicaltrials.gov Identifier: NCT00314184 J Clin Psychiatry © Copyright 2011 Physicians Postgraduate Press, Inc. Submitted: January 24, 2011; accepted July 28, 2011. Online ahead of print: October 18, 2011 (doi:10.4088/JCP.11m06878). Corresponding author: Richard H. Weisler, MD, Department of Psychiatry and Behavioral Science, Duke University Medical Center, Department of Psychiatry, University of North Carolina at Chapel Hill, 700 Spring Forest, Ste 125, Raleigh, NC 27609 (RWeisler@aol.com).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lithium (level 1),368, 369 quetiapine (level 1),369, 370 divalproex (level 1) 369, 371, 372 (Figure 4) and lamotrigine (level 1)369, 373 monotherapies have the best combination of clinical trials, administrative data, and clinical experience to support their use as first‐line therapies for maintenance treatment of BD.”
In the citing paper
“Further, there is evidence that oral quetiapine and long‐acting injectable risperidone monotherapy and adjunctive therapy and oral ziprasidone adjunctive therapy are effective in preventing mood episodes in adults with BD.369, 370, 383, 384, 387”
Citations
Cites
Still being checked.
Cited by
Items 101–168 of 168
The pseudoscience of lithium and suicide: Reanalysis of a misleading meta-analysis
Ghaemi, S. N. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241257833 · Cited by 7
Weisler, R. H., McIntyre, R. S., & Bauer, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.846519 · Cited by 8
Self-citationKishi, T., Sakuma, K., Okuya, M., Matsuda, Y., Esumi, S., Hashimoto, Y., Hatano, M., Miyake, N., Miura, I., Miyahara, K., et al. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001264 · Cited by 12
The Treatment of Bipolar Depression: Current Status and Future Perspectives
Jelen, L. A., & Young, A. H. (2020) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-020-00200-x · Cited by 7
Pharmacoepidemiology and Clinical Correlates of Lithium Treatment for Bipolar Disorder in Asia
Shuy, Y. K., Santharan, S., Chew, Q. H., Lin, S., Ouyang, W., Chen, C., Park, S., Jang, O., Park, J. H., Chee, K., et al. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001813 · Cited by 7
Licht, R. W., & Severus, E. (2014) · International Journal of Bipolar Disorders · doi:10.1186/s40345-014-0008-7 · Cited by 5
Thangavel, M., Raj, T. S., Chinnappan, S., Anbalagan, M., Arunagirinathan, N., Kuvin, E., Pattabi, S., Paranjothy, C., & Mani, R. R. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.10.003 · Cited by 3
Fountoulakis, K. N. (2014) · Springer eBooks · doi:10.1007/978-3-642-37216-2_16 · Cited by 3
A Brief History of Psychopharmacology
Haddad, P. M., Nutt, D. J., & Green, A. R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.003 · Cited by 4
Emerging drugs for bipolar depression: an update
Keedwell, P. A., & Young, A. H. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.872628 · Cited by 3
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_31 · Cited by 3
Lithium: Emerging frontiers in metallopharmaceutical therapeutics
Tong, S., Xiao, J., Zhang, X., & Ma, J. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.07.001 · Cited by 2
Licht, R. W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-405170-6.00010-5 · Cited by 2
Actualización en el uso y el manejo del litio en neuropsiquiatría
Corrales, A., Cetkovich, M., Abadi, A. F., Camino, S., Bonetto, G. G., Mato, A. M. L., Marengo, E., Abraham, E., Maresca, T., Bagnati, P. R. A. D. N., et al. (2024) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i162.504 · Cited by 2
Eficacia de quetiapina de liberación prolongada en la sintomatología afectiva
Álamo, C., & Lopez-Munoz, F. J. (2012) · Revista de Psiquiatría y Salud Mental · doi:10.1016/s1888-9891(12)70012-5 · Cited by 3
Bipolar and Psychotic Disorders
Currie, A., & McAllister-Williams, H. (2022) · Springer eBooks · doi:10.1007/978-3-031-08364-8_12 · Cited by 1
Treatment of bipolar disorder: not another meta-analysis
Grunze, H. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70350-5 · Cited by 1
Extended-release quetiapine fumarate in the treatment of bipolar disorder
Weerasundera, R., & Castle, D. J. (2012) · Neuropsychiatry · doi:10.2217/npy.12.48 · Cited by 1
Maintenance Treatment with Lithium
Bauer, M., & Gitlin, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-31214-9_5 · Cited by 1
Lithium and Its Role in Psychiatry
Kamali, M., Ostacher, M. J., & Perlis, R. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00053-9 · Cited by 1
Indications curative et préventive dans le trouble bipolaire
Pitchot, W. (2014) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2014.02.008 · Cited by 1
Pharmacological Treatment of the Maintenance Phase of Bipolar Depression: Efficacy and Side Effects
Gao, K., Wu, R., & Calabrese, J. R. (2016) · Milestones in drug therapy · doi:10.1007/978-3-319-31689-5_10 · Cited by 3
Thom, R. P., Teslyar, P., Kirby, A. E., Fong, T. G., Friedman, R. S., Brady, R. O., & Bloomingdale, K. L. (2017) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000143 · Cited by 1
Essential Pharmacotherapies for Bipolar Disorder
Ruegg, H., Adler, C. M., Durán, L. R. P., Watson, S., & DelBello, M. P. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-018-0162-0 · Cited by 1
Diagnostik und Therapie bipolarer Störungen
Beier, F., Severus, E., & Bauer, M. (2020) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-020-1516-x · Cited by 1
Bauer, M., Severus, E., & Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_68 · Cited by 1
Irizarry, R., Gomez, A. E. S., Miles, S., & Acosta, J. T. (2022) · Case Reports in Psychiatry · doi:10.1155/2022/3813929 · Cited by 1
Drug therapy for bipolar disorder: A review of efficacy evidence
Bourin, M. (2023) · Archives of Depression and Anxiety · doi:10.17352/2455-5460.000085 · Cited by 1
Bipolar Disorder: Diagnosis, Clinical Features, Outcome and Treatment
Burgess, J. L., Currie, A., Watson, S., Sharma, A., Cousins, D. A., Cookson, J., & McAllister-Williams, H. (2024) · Cambridge University Press eBooks · doi:10.1017/9781911623861.008 · Cited by 2
Goñi, J. M. R., Castilla‐Rodríguez, I., Valcárcel‐Nazco, C., Castresana, C. D. L. C., Mar, J., & Aguilar, P. S. (2015) · PharmacoEconomics Spanish Research Articles · doi:10.1007/s40277-015-0042-6 · Cited by 1
Sustained Hyperparathyroidism Among Patients Treated With Lithium
Lozano, R., Marín, R., Santacruz, M.-J., & Pascual, A. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000473 · Cited by 1
McGrath, P. J., & Roose, S. P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.004
Alberdi, G., & Manuel, J. (2012) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Pharmacological Management of Manic Episodes
Vieta, E. (2013) · doi:10.1007/978-1-908517-94-4_8
Comprehensive Pharmacologic Management of Bipolar Depression
McGirr, A., & Bond, D. J. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0017-2
Benkert, O., Hautzinger, M., Graf-Morgenstern, M., Paulzen, M., & Himmerich, H. (2016) · Springer eBooks · doi:10.1007/978-3-662-49092-1_15
Tratamiento a largo plazo del trastorno bipolar: papel de los antipsicóticos
de Dios, C. (2015) · Psiquiatría Biológica · doi:10.1016/s1134-5934(15)30009-9
Pharmacologic and somatic treatments for bipolar depression
Giner, L., Kelly, S. A., & Oquendo, M. A. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.007
Beyond Lithium: Other Treatments for Bipolar Disorder
Bauer, M., & Gitlin, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-31214-9_13
Medication treatment of mania: Acute and preventive
Kahn, D. A. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.008
Meist lebenslange Rezidivprophylaxe erforderlich: Bipolare Manie
Messer, T., Tiltscher, C., & Schmauß, M. (2012) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-012-0496-1
Lithium in Acute and Maintenance Treatment of Bipolar Disorders
Henry, C., Dargél, A., & Scott, J. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-45923-3_12
Quetiapine Review of its Use in the Management of
Cassidy, F., Psychiatry, C., Menke, A., & Suzuki, T. (2012)
Pharmacological treatment of bipolar disorder
Dell’Osso, B. M. (2013) · doi:10.2217/ebo.13.150
Lithium in der Langzeittherapie der bipolaren Störung — was gibt es Neues?
Petzold, J., Bauer, M., & Severus, E. (2017) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-017-1742-3
Lithium ist Quetiapin überlegen
Lieb, K. (2017) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-017-2277-z
Maruta, N. (2019) · Ukrains kyi Visnyk Psykhonevrolohii · doi:10.36927/2079-0325-v27-is4-2019-18
Are (Some) Antipsychotics Depressogenic in Bipolar Disorder?
Goldberg, J. F. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20com13284 · Cited by 1
Chen, G., Machado‐Vieira, R., Zarate, C. A., & Manji, H. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_10033
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. ‐. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_31-1
Bauer, M., Severus, E., & Laux, G. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_68-1
Chen, G., Machado‐Vieira, R., Zarate, C. A., & Manji, H. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_10033-1
Young, A. H., & Sually, D. S. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.013
Cetkovich, M., Abadi, A. F., Camino, S., Bonetto, G. G., Herbst, L., Marengo, E., Torrente, F. M., Maresca, T., Bustin, J., Morra, C. A., et al. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i159.363
Meyer, J. M., & Stahl, S. M. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009225069.004
Almeida, J., Spelber, D., & Smith, T. L. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as37 · Cited by 2
Lithium and Its Role in Psychiatry
Kamali, M., Ostacher, M. J., & Perlis, R. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11972-9.00004-1
Lithium and Mental Health: The Small Element with a Big Impact
Cruvinel, I. D., Zanuzzi, T. R. L., & de Oliveira, F. M. (2025) · OALib · doi:10.4236/oalib.1113282
Antipsychotic medications in affective disorders
Vázquez, G. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33580-8.00009-x
Strawn, J. R., & Stahl, S. M. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009642187.053
Lithium and long-term cognitive outcomes in bipolar disorder and early dementia: a systematic review
Deng, R., Shargorodsky, A., Teopiz, K. M., Dri, C. E., Wong, S., Le, G. H., Zheng, Y. J., & McIntyre, R. S. (2026) · CNS Spectrums · doi:10.1017/s1092852926100996 · Cited by 1
Prisco, M. D., Oliva, V., Miola, A., Fornaro, M., Dragioti, E., Croatto, G., Carvalho, A. F., Berk, M., Nikolitch, K., Saraf, G., et al. (2026) · BMJ · doi:10.1136/bmj-2026-100216
Psychopharmakotherapie – klinisch-empirische Grundlagen
Kasper, S. F., Hasan, A., & Möller, H. (2026) · Springer Reference Medizin · doi:10.1007/978-3-642-45028-0_31-2
Metadata
- Authors
- Weisler, R. H., Nolen, W. A., Neijber, A., Hellqvist, Å., Paulsson, B., & Trial 144 Study Investigators
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Weisler, Richard H.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-11-15
- Volume
- 72
- Issue
- 11
- Pages
- 1452-1464
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2034480582
- Cited by
- 169
- References
- 0
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 8 · 2022: 4 · 2021: 8 · 2020: 10 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 12 · 2015: 15 · 2014: 23 · 2013: 23 · 2012: 15
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Universidad Peruana Cayetano Heredia Institutional Repository (submittedVersion, cc-by-nc-nd)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- quetiapine, bipolar I disorder, maintenance therapy, lithium, mood stabilizers, relapse prevention, manic episodes, depressive episodes, drug switching, adverse events, atypical antipsychotics, lithium toxicity, divalproex, open-label extension, early trial termination
- MeSH terms
- Quetiapine Fumarate, Adult, Bipolar Disorder, Dibenzothiazepines, Double-Blind Method, Female, Humans, Lithium, Male, Middle Aged, Placebos, Antipsychotic Agents, Proportional Hazards Models, Treatment Outcome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.